<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10588">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00645671</url>
  </required_header>
  <id_info>
    <org_study_id>525</org_study_id>
    <nct_id>NCT00645671</nct_id>
  </id_info>
  <brief_title>Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery</brief_title>
  <official_title>A Randomized Multicenter, Double-Masked, Parallel-Group Clinical Safety and Efficacy Evaluation of Loteprednol Etabonate Ophthalmic Ointment, 0.5% Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the clinical safety and efficacy of Loteprednol Etabonate Ophthalmic Ointment,
      0.5% vs. vehicle for the treatment of inflammation following cataract surgery
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Subjects With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0.</measure>
    <time_frame>Postoperative Day 8 (Visit 5)</time_frame>
    <safety_issue>No</safety_issue>
    <description>A combination of the grades for inflammatory cells and flare in the anterior chamber. Cells: accumulation of white blood cells in aqueous. 0=No cells seen; 1=1-5 cells; 2=6-15 cells; 3=16-30 cells; 4= &gt;30 cells. Flare: Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). 0=None; 1=Mild; 2=Moderate; 3=Severe; 4=Very severe.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade 0 for Pain</measure>
    <time_frame>Postoperative Day 8 (Visit 5)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pain: A positive sensation of the eye, including foreign body sensation, stabbing, throbbing, or aching. Grade 0 = None; 1=Minimal; 2=Mild; 3=Moderate; 4=Moderately Severe; 5=Severe</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects With Complete Resolution of Anterior Chamber Cells and Flare. At Each Follow-up Visit.</measure>
    <time_frame>At each follow-up visit through day18 (Visit 7)</time_frame>
    <safety_issue>No</safety_issue>
    <description>A combination of the grades for inflammatory cells and flare in the anterior chamber. Cells: accumulation of white blood cells in aqueous. 0=No cells seen; 1=1-5 cells; 2=6-15 cells; 3=16-30 cells; 4= &gt;30 cells. Flare: Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). 0=None; 1=Mild; 2=Moderate; 3=Severe; 4=Very severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Each Follow-up Visit in Anterior Chamber Cells and Flare</measure>
    <time_frame>Baseline and each follow-up visit through day18 (Visit 7)</time_frame>
    <safety_issue>No</safety_issue>
    <description>A combination of the grades for inflammatory cells and flare in the anterior chamber. Cells: accumulation of white blood cells in aqueous. 0=No cells seen; 1=1-5 cells; 2=6-15 cells; 3=16-30 cells; 4= &gt;30 cells. Flare: Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). 0=None; 1=Mild; 2=Moderate; 3=Severe; 4=Very severe.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Ocular Inflammation</condition>
  <arm_group>
    <arm_group_label>Loteprednol Etabonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loteprednol etabonate 0.5% ophthalmic ointment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle of loteprednol etabonate ointment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5% Loteprednol Etabonate Ophthalmic Ointment</intervention_name>
    <description>1/2 inch ribbon four times a day for 14 days</description>
    <arm_group_label>Loteprednol Etabonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle of Loteprednol Etabonate Ophthalmic Ointment</intervention_name>
    <description>1/2 inch ribbon four times a day for 14 days</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who are candidate for routine, uncomplicated cataract surgery

          2. Subjects who, in the Investigator's opinion, have potential postoperative pinholed
             Snellen visual acuity (VA) of at least 20/200 in the study eye.

        Exclusion Criteria:

          1. Subjects who will require concurrent ocular therapy with NSAIDs, mast cell
             stabilizers, antihistamines, decongestants, or immunosuppressants (e.g., Restasis),
             or with ocular or systemic corticosteroids

          2. Subjects who have known hypersensitivity or contraindication to the study drug(s) or
             their components

          3. Subjects who are monocular or have pinholed Snellen VA 20/200 or worse in the
             non-study eye

          4. Subjects who have had ocular surgery (including laser surgery) in the study eye
             within 3 months or in the fellow eye within 2 weeks prior to the Screening Visit
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alyson J Berliner, MD/PhD</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>John Hunkeler, MD</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 4, 2015</lastchanged_date>
  <firstreceived_date>March 13, 2008</firstreceived_date>
  <firstreceived_results_date>June 28, 2010</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Loteprednol etabonate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 400 subjects, 18 years old or older who were candidates for routine, uncomplicated cataract surgery, were enrolled at 17 investigative sites in the US. First subject was enrolled on 3/14/2008 and last subject visit was 3/23/2009.</recruitment_details>
      <pre_assignment_details>Following cataract surgery at visit 3 (post operative day 1), subjects were assessed for eligibility. 201 subjects were randomized to receive loteprednol etabonate ointment and 199 to receive its vehicle.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Loteprednol Etabonate</title>
          <description>Loteprednol etabonate 0.5% ophthalmic ointment</description>
        </group>
        <group group_id="P2">
          <title>Vehicle</title>
          <description>Vehicle of loteprednol etabonate ointment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="201"/>
                <participants group_id="P2" count="199"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="193"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Loteprednol Etabonate</title>
          <description>Loteprednol etabonate 0.5% ophthalmic ointment</description>
        </group>
        <group group_id="B2">
          <title>Vehicle</title>
          <description>Vehicle of loteprednol etabonate ointment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="201"/>
                <measurement group_id="B2" value="199"/>
                <measurement group_id="B3" value="400"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="69.2" spread="9.39"/>
                <measurement group_id="B2" value="69.2" spread="8.77"/>
                <measurement group_id="B3" value="69.2" spread="9.08"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="118"/>
                <measurement group_id="B2" value="119"/>
                <measurement group_id="B3" value="237"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="83"/>
                <measurement group_id="B2" value="80"/>
                <measurement group_id="B3" value="163"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="7"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="29"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="183"/>
                <measurement group_id="B2" value="179"/>
                <measurement group_id="B3" value="362"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjects With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0.</title>
        <description>A combination of the grades for inflammatory cells and flare in the anterior chamber. Cells: accumulation of white blood cells in aqueous. 0=No cells seen; 1=1-5 cells; 2=6-15 cells; 3=16-30 cells; 4= &gt;30 cells. Flare: Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). 0=None; 1=Mild; 2=Moderate; 3=Severe; 4=Very severe.</description>
        <time_frame>Postoperative Day 8 (Visit 5)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol Etabonate</title>
            <description>Loteprednol etabonate 0.5% ophthalmic ointment</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of loteprednol etabonate ointment</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="201"/>
                  <measurement group_id="O2" value="199"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Subjects With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0.</title>
            <description>A combination of the grades for inflammatory cells and flare in the anterior chamber. Cells: accumulation of white blood cells in aqueous. 0=No cells seen; 1=1-5 cells; 2=6-15 cells; 3=16-30 cells; 4= &gt;30 cells. Flare: Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). 0=None; 1=Mild; 2=Moderate; 3=Severe; 4=Very severe.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Yes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>No</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="153"/>
                  <measurement group_id="O2" value="172"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Complete Resolution of Anterior Chamber Cells and Flare. At Each Follow-up Visit.</title>
        <description>A combination of the grades for inflammatory cells and flare in the anterior chamber. Cells: accumulation of white blood cells in aqueous. 0=No cells seen; 1=1-5 cells; 2=6-15 cells; 3=16-30 cells; 4= &gt;30 cells. Flare: Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). 0=None; 1=Mild; 2=Moderate; 3=Severe; 4=Very severe.</description>
        <time_frame>At each follow-up visit through day18 (Visit 7)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol Etabonate</title>
            <description>Loteprednol etabonate 0.5% ophthalmic ointment</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of loteprednol etabonate ointment</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="201"/>
                  <measurement group_id="O2" value="199"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Subjects With Complete Resolution of Anterior Chamber Cells and Flare. At Each Follow-up Visit.</title>
            <description>A combination of the grades for inflammatory cells and flare in the anterior chamber. Cells: accumulation of white blood cells in aqueous. 0=No cells seen; 1=1-5 cells; 2=6-15 cells; 3=16-30 cells; 4= &gt;30 cells. Flare: Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). 0=None; 1=Mild; 2=Moderate; 3=Severe; 4=Very severe.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Visit 4 (postoperative day 3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Visit 5 (postoperative day 8)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Visit 6 (postoperative day 15)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="84"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Visit 7 (postoperative day 18)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="86"/>
                  <measurement group_id="O2" value="39"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Each Follow-up Visit in Anterior Chamber Cells and Flare</title>
        <description>A combination of the grades for inflammatory cells and flare in the anterior chamber. Cells: accumulation of white blood cells in aqueous. 0=No cells seen; 1=1-5 cells; 2=6-15 cells; 3=16-30 cells; 4= &gt;30 cells. Flare: Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). 0=None; 1=Mild; 2=Moderate; 3=Severe; 4=Very severe.</description>
        <time_frame>Baseline and each follow-up visit through day18 (Visit 7)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol Etabonate</title>
            <description>Loteprednol etabonate 0.5% ophthalmic ointment</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of loteprednol etabonate ointment</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="201"/>
                  <measurement group_id="O2" value="199"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline to Each Follow-up Visit in Anterior Chamber Cells and Flare</title>
            <description>A combination of the grades for inflammatory cells and flare in the anterior chamber. Cells: accumulation of white blood cells in aqueous. 0=No cells seen; 1=1-5 cells; 2=6-15 cells; 3=16-30 cells; 4= &gt;30 cells. Flare: Scattering of a slit lamp light beam when directed into the anterior chamber (Tyndall effect). 0=None; 1=Mild; 2=Moderate; 3=Severe; 4=Very severe.</description>
            <units>Composit scores</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Visit 4 (postoperative day 3)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.0" spread="1.08"/>
                  <measurement group_id="O2" value="-0.4" spread="1.42"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Visit 5 (postoperative day 8)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.1" spread="1.31"/>
                  <measurement group_id="O2" value="-0.7" spread="1.81"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Visit 6 (postoperative day 15)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.6" spread="1.37"/>
                  <measurement group_id="O2" value="-0.9" spread="1.97"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Visit 7 (postoperative day 18)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.5" spread="1.45"/>
                  <measurement group_id="O2" value="-1.1" spread="1.95"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Grade 0 for Pain</title>
        <description>Pain: A positive sensation of the eye, including foreign body sensation, stabbing, throbbing, or aching. Grade 0 = None; 1=Minimal; 2=Mild; 3=Moderate; 4=Moderately Severe; 5=Severe</description>
        <time_frame>Postoperative Day 8 (Visit 5)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Loteprednol Etabonate</title>
            <description>Loteprednol etabonate 0.5% ophthalmic ointment</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Vehicle of loteprednol etabonate ointment</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="201"/>
                  <measurement group_id="O2" value="199"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Grade 0 for Pain</title>
            <description>Pain: A positive sensation of the eye, including foreign body sensation, stabbing, throbbing, or aching. Grade 0 = None; 1=Minimal; 2=Mild; 3=Moderate; 4=Moderately Severe; 5=Severe</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Yes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="156"/>
                  <measurement group_id="O2" value="90"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>No</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45"/>
                  <measurement group_id="O2" value="109"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The LE treatment group had a mean exposure of 13.2 days (+/-3.06), the vehicle treatment group mean exposure was 9.2 days (+/-5.10). Mean days of exposure was &lt; 14 days due to the use of rescue medication, especially in the vehicle group.</time_frame>
      <desc>Ocular AE's in study eyes and were reported prior to rescue medication use - safety population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Loteprednol Etabonate</title>
          <description>Loteprednol etabonate 0.5% ophthalmic ointment</description>
        </group>
        <group group_id="E2">
          <title>Vehicle</title>
          <description>Vehicle of loteprednol etabonate ointment</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <description>unrelated to study drug and study participation, due to a concurrent condition</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <description>Unrelated to study drug but related to the cataract surgery.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Post-operative inflammation</sub_title>
                <description>Corneal Macular Edema, possibley related to study drug, probably related to study participation.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <description>Unrelated to study drug and study participation, associated with an accidental injury.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="201"/>
                <counts group_id="E2" subjects_affected="161" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Anterior chamber cell</sub_title>
                <counts group_id="E1" events="15" subjects_affected="5" subjects_at_risk="201"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title vocab="MedDRA">Anterior chamber inflammation</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="167" subjects_affected="61" subjects_at_risk="201"/>
                <counts group_id="E2" events="167" subjects_affected="106" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Ciliary hyperemia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="5" subjects_at_risk="201"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="25" subjects_affected="10" subjects_at_risk="201"/>
                <counts group_id="E2" events="25" subjects_affected="15" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Corneal edema</sub_title>
                <counts group_id="E1" events="19" subjects_affected="8" subjects_at_risk="201"/>
                <counts group_id="E2" events="19" subjects_affected="11" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="34" subjects_affected="8" subjects_at_risk="201"/>
                <counts group_id="E2" events="34" subjects_affected="26" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Iritis</sub_title>
                <counts group_id="E1" events="30" subjects_affected="11" subjects_at_risk="201"/>
                <counts group_id="E2" events="30" subjects_affected="19" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="20" subjects_affected="6" subjects_at_risk="201"/>
                <counts group_id="E2" events="20" subjects_affected="14" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Ocular hyperemia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="5" subjects_at_risk="201"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Ocular pruritis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="5" subjects_at_risk="201"/>
                <counts group_id="E2" events="21" subjects_affected="16" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="36" subjects_affected="17" subjects_at_risk="201"/>
                <counts group_id="E2" events="36" subjects_affected="19" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with, the Sponsor and such that confidential or proprietary information is not disclosed.
Prior to publication or presentation, a copy of the final text should be forwarded by the Investigator(s) to the Sponsor or its designee for comment.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Tuyen Ong</name_or_title>
      <organization>Bausch &amp; Lomb</organization>
      <phone>(973) 360-6389</phone>
      <email>Tuyen.Ong@bausch.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
